Pharmacy

Your Article Summary

See Latest Articles

Prucalopride: the evidence for its use in the treatment of chronic constipation
Core Evidence, 08/05/09

Coremans G – Prucalopride 1–2 mg once daily may be given to patients suffering from chronic constipation for whom laxatives do not provide adequate relief of their symptoms. Patients with severe constipation and slow transit, who frequently develop tolerance to stimulant laxatives, are also eligible for prucalopride treatment. There are now convincing data from phase II and multicenter phase III randomized, double–blind, placebo–controlled trials that prucalopride treatment results in a clinically meaningful increase in the number of spontaneous complete bowel movements, a reduction of perceived severity of symptoms and improved disease–related quality of life in a significant proportion of patients. There is a rapid onset of the effect and the improvement is maintained for at least 12 weeks. Prucalopride in a dose of up to 4 mg per day appeared generally well tolerated and devoid of serious cardiac events. Adverse events, most frequently headache and nausea, are usually mild or moderate and occur mainly during the first days of treatment.

Today in Stomach/GI...keeping you current

Receive free subspecialty "5-minute updates" via email

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09

Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin
Journal of Viral Hepatitis, 11/09/09

Methotrexate for maintenance of remission in Crohn's disease
Cochrane Reviews, 10/27/09

See All of Stomach/GI